PFSA Stock Forecast: Profusa, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 19 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Profusa, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (88): Sales and profits are climbing, and climbing faster than before.
Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PFSA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PFSA, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
PFSA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PFSA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 99% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −56.5%
- Dividend yield
- —
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Profusa, Inc. has a market value of $1.8M and an enterprise value of $8.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$43.0M.
Free cash flow in the twelve months to 30 June 2026: −$20.4M.
Trailing P/E: 0.0×.
Data provided by Twelve Data
PFSA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PFSA’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Profusa, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PFSA
How does Ticker Nerd's model rank PFSA?
As at 21 Nov 2026, Profusa, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).
What is the PFSA stock forecast for 2030?
No analyst covering Profusa, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFSA are extrapolating price history, which says nothing about the business.
What does Profusa, Inc. do?
Profusa Inc. Common Stock represents the equity of Profusa, Inc., a digital health and medical technology company based in Berkeley, California. Profusa develops bioengineered, body-integrated sensors designed to continuously detect and transmit clinical-grade data for personal and medical use.
About Profusa, Inc.
Profusa Inc. Common Stock represents the equity of Profusa, Inc., a digital health and medical technology company based in Berkeley, California. Profusa develops bioengineered, body-integrated sensors designed to continuously detect and transmit clinical-grade data for personal and medical use. Its current product lineup includes the Lumee Oxygen Platform, which is used to monitor tissue oxygen levels in settings such as peripheral artery disease, chronic wounds, and reconstructive surgery, as well as the Lumee Glucose Platform, which is being developed to measure glucose levels in interstitial fluid. The company operates at the intersection of biosensing, medical devices, and digital health, serving applications in chronic disease management and real-time physiological monitoring. Profusa’s common stock provides public-market exposure to a company focused on continuous biomarker sensing technologies for healthcare professionals and patients.
CEO Mr. Jack E. Stover CPA · United States · https://profusa.com